MOLECULAR TEMPLATES INC (MTEM) Fundamental Analysis & Valuation

NASDAQ:MTEM • US6085502085

Current stock price

0.1072 USD
-0.03 (-23.43%)
At close:
0.1113 USD
+0 (+3.82%)
After Hours:

This MTEM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MTEM Profitability Analysis

1.1 Basic Checks

  • In the past year MTEM has reported negative net income.
  • In the past year MTEM has reported a negative cash flow from operations.
  • In the past 5 years MTEM always reported negative net income.
  • In the past 5 years MTEM always reported negative operating cash flow.
MTEM Yearly Net Income VS EBIT VS OCF VS FCFMTEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

  • MTEM has a Return On Assets of -58.52%. This is comparable to the rest of the industry: MTEM outperforms 41.83% of its industry peers.
  • With a Return On Equity value of -219.70%, MTEM is not doing good in the industry: 69.66% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -58.52%
ROE -219.7%
ROIC N/A
ROA(3y)-53.73%
ROA(5y)-55.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTEM Yearly ROA, ROE, ROICMTEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 -400 600 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MTEM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTEM Yearly Profit, Operating, Gross MarginsMTEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MTEM Health Analysis

2.1 Basic Checks

  • MTEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MTEM has been increased compared to 1 year ago.
  • MTEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MTEM Yearly Shares OutstandingMTEM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
MTEM Yearly Total Debt VS Total AssetsMTEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • MTEM has an Altman-Z score of -25.30. This is a bad value and indicates that MTEM is not financially healthy and even has some risk of bankruptcy.
  • MTEM has a worse Altman-Z score (-25.30) than 89.77% of its industry peers.
  • MTEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -25.3
ROIC/WACCN/A
WACC10.24%
MTEM Yearly LT Debt VS Equity VS FCFMTEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.56 indicates that MTEM should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.56, MTEM is doing worse than 81.87% of the companies in the same industry.
  • A Quick Ratio of 1.56 indicates that MTEM should not have too much problems paying its short term obligations.
  • MTEM has a Quick ratio of 1.56. This is amonst the worse of the industry: MTEM underperforms 80.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.56
MTEM Yearly Current Assets VS Current LiabilitesMTEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MTEM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 78.35% over the past year.
  • Looking at the last year, MTEM shows a very negative growth in Revenue. The Revenue has decreased by -49.41% in the last year.
  • The Revenue has been growing by 33.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)78.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.84%
Revenue 1Y (TTM)-49.41%
Revenue growth 3Y44.86%
Revenue growth 5Y33.95%
Sales Q2Q%-91.67%

3.2 Future

  • The Earnings Per Share is expected to decrease by -19.70% on average over the next years. This is quite bad
  • MTEM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.69% yearly.
EPS Next Y-92.81%
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%
EPS Next 5Y-19.7%
Revenue Next Year-78.76%
Revenue Next 2Y-85.29%
Revenue Next 3Y-46.28%
Revenue Next 5Y-10.69%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MTEM Yearly Revenue VS EstimatesMTEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M
MTEM Yearly EPS VS EstimatesMTEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

0

4. MTEM Valuation Analysis

4.1 Price/Earnings Ratio

  • MTEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTEM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTEM Price Earnings VS Forward Price EarningsMTEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTEM Per share dataMTEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • MTEM's earnings are expected to decrease with -21.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MTEM Dividend Analysis

5.1 Amount

  • MTEM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MTEM Fundamentals: All Metrics, Ratios and Statistics

MOLECULAR TEMPLATES INC

NASDAQ:MTEM (12/24/2024, 7:26:55 PM)

After market: 0.1113 +0 (+3.82%)

0.1072

-0.03 (-23.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11
Earnings (Next)N/A
Inst Owners56.12%
Inst Owner Change2281000%
Ins Owners3.96%
Ins Owner Change0%
Market Cap705.38K
Revenue(TTM)25.47M
Net Income(TTM)-15.62M
Analysts82.86
Price Target18.36 (17026.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)63.16%
Min EPS beat(2)16.26%
Max EPS beat(2)110.06%
EPS beat(4)4
Avg EPS beat(4)48.67%
Min EPS beat(4)16.26%
Max EPS beat(4)110.06%
EPS beat(8)7
Avg EPS beat(8)48.91%
EPS beat(12)10
Avg EPS beat(12)36.51%
EPS beat(16)12
Avg EPS beat(16)-1.05%
Revenue beat(2)2
Avg Revenue beat(2)57.36%
Min Revenue beat(2)30.42%
Max Revenue beat(2)84.31%
Revenue beat(4)3
Avg Revenue beat(4)68.38%
Min Revenue beat(4)-11.54%
Max Revenue beat(4)170.33%
Revenue beat(8)6
Avg Revenue beat(8)235.75%
Revenue beat(12)8
Avg Revenue beat(12)154.87%
Revenue beat(16)8
Avg Revenue beat(16)104.62%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.1
P/tB 0.1
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.4
Fwd EYN/A
FCF(TTM)-3.64
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS3.87
BVpS1.08
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.52%
ROE -219.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.73%
ROA(5y)-55.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.56
Quick Ratio 1.56
Altman-Z -25.3
F-Score4
WACC10.24%
ROIC/WACCN/A
Cap/Depr(3y)35.57%
Cap/Depr(5y)222.6%
Cap/Sales(3y)8.96%
Cap/Sales(5y)21.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.84%
EPS Next Y-92.81%
EPS Next 2Y-24.36%
EPS Next 3Y-21.57%
EPS Next 5Y-19.7%
Revenue 1Y (TTM)-49.41%
Revenue growth 3Y44.86%
Revenue growth 5Y33.95%
Sales Q2Q%-91.67%
Revenue Next Year-78.76%
Revenue Next 2Y-85.29%
Revenue Next 3Y-46.28%
Revenue Next 5Y-10.69%
EBIT growth 1Y57.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.4%
OCF growth 3YN/A
OCF growth 5YN/A

MOLECULAR TEMPLATES INC / MTEM Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MOLECULAR TEMPLATES INC (MTEM) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MTEM.


What is the valuation status of MOLECULAR TEMPLATES INC (MTEM) stock?

ChartMill assigns a valuation rating of 0 / 10 to MOLECULAR TEMPLATES INC (MTEM). This can be considered as Overvalued.


What is the profitability of MTEM stock?

MOLECULAR TEMPLATES INC (MTEM) has a profitability rating of 0 / 10.


What is the financial health of MOLECULAR TEMPLATES INC (MTEM) stock?

The financial health rating of MOLECULAR TEMPLATES INC (MTEM) is 5 / 10.